Showing 95 results

Filters Content type: News, Editors' picks, About HIV Topic: Injectable & long-acting PrEP

The antiretroviral drug cabotegavir, administered every eight weeks as an injection, has been shown to be safe and effective in preventing HIV infection in men who have sex with men. Studies in women are ongoing and scientists are also working on a long-acting PrEP implant.

New & experimental HIV treatments

Merck restarts islatravir HIV treatment studies, but abandons monthly PrEP

News
23 September 2022
Transmission & prevention

aidsmapLIVE: HIV prevention Video

September 2022
Transgender people

Injectable PrEP is just as effective for transgender women as it is for gay men, study analysis finds

News
11 August 2022
Injectable & long-acting PrEP

Preventive HIV drug shows urgent need for transparency on pricing

Editor's pick
Nature (editorial)
10 August 2022
Global health initiatives

aidsmapLIVE: AIDS 2022 special Video

August 2022
Injectable & long-acting PrEP

Injectable PrEP can only cost a little more than oral PrEP if it is to be cost-effective, South African study finds

News
3 August 2022
Access to healthcare

Just six injections a year can prevent HIV: here’s what it will take for the world to afford them

News
2 August 2022
Access to healthcare

ViiV Healthcare to allow 90 countries to access generic versions of HIV prevention shot

News
28 July 2022
Injectable & long-acting PrEP

ViiV Healthcare and the Medicines Patent Pool sign new voluntary licensing agreement to expand access to innovative long-acting HIV prevention medicine

Editor's pick
Medicines Patent Pool
28 July 2022
Injectable & long-acting PrEP

UNAIDS welcomes ViiV’s agreement to enable generic production of long acting PrEP to 90 countries

Editor's pick
UNAIDS
28 July 2022
Injectable & long-acting PrEP

Injectable and long-acting PrEP A research briefing

About HIV
July 2022
Injectable & long-acting PrEP

Long-lasting HIV prevention drug too slow to reach Africa, activists say

Editor's pick
Science
22 June 2022
Access to healthcare

New AVAC Plan Lays Out Priorities for Swift and Equitable Rollout of Injectable Cabotegravir for PrEP

Editor's pick
AVAC
13 June 2022
Access to healthcare

ViiV Healthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for PrEP to Medicines Patent Pool

Editor's pick
ViiV Healthcare
27 May 2022
Access to healthcare

ViiV ‘actively negotiating’ voluntary licence for HIV prevention drug

Editor's pick
Financial Times
27 May 2022
PrEP programmes & uptake

US: Black Women Prefer HIV Prevention Shots, But Cost is a Factor

Editor's pick
POZ
22 April 2022
Injectable & long-acting PrEP

ViiV Healthcare is working with Medicines Patent Pool to progress voluntary licensing for cabotegravir long-acting for PrEP

Editor's pick
ViiV press release
4 April 2022
Injectable & long-acting PrEP

What is the use of anti-HIV injections when those who need it most can't use it?

Editor's pick
Bhekisisa
31 March 2022
Injectable & long-acting PrEP

No breakthrough HIV infections seen in women using injectable PrEP

News
25 March 2022
Injectable & long-acting PrEP

Community Response to ViiV’s Recent Statements on CAB-LA

Editor's pick
AfroCAB
18 March 2022
Injectable & long-acting PrEP

Unitaid to introduce new long-lasting injection to prevent HIV in Brazil and South Africa, as high-income countries begin deployment

Editor's pick
Unitaid
18 March 2022
Injectable & long-acting PrEP

MSF response: ViiV will not license new game-changing long-acting HIV prevention drug to generic manufacturers

Editor's pick
Médecins Sans Frontières
4 March 2022
Injectable & long-acting PrEP

ViiV Healthcare statement on voluntary license in enabling access to cabotegravir LA for PrEP in low- and middle-income countries

Editor's pick
ViiV Healthcare
4 March 2022
Injectable & long-acting PrEP

Communities demand ViiV/GSK accelerate access to CAB-LA in LMICs

Editor's pick
AfroCAB
1 March 2022